StockData
Cerenome, Inc. logo

Cerenome, Inc. (CNSY) stock

CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3067% below fair value
$0.71+0.08 (+12.14%)

Close on Nov 18, 2026Market cap $5.36MP/E –Yield –

Cerenome revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Cerenome's revenue for the twelve months ending Jun 30, 2026 was $4.20M, down 21.0% year over year. For fiscal 2025 it was $5.21M, down 10.5% from the year before. Over ten years it grew -4.2% a year on average. The highest annual figure on record is $8.71M in fiscal 2012.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.21M-10.5%
FY2024Dec 31, 2024$5.82M+18.5%
FY2023Dec 31, 2023$4.91M+33.8%
FY2018Dec 31, 2018$3.67M+36.5%
FY2017Dec 31, 2017$2.69M-42.2%
FY2016Dec 31, 2016$4.66M-3.8%
FY2015Dec 31, 2015$4.84M-2.3%
FY2014Dec 31, 2014$4.95M-30.5%
FY2013Dec 31, 2013$7.12M-18.2%
FY2012Dec 31, 2012$8.71M+9.1%
FY2011Dec 31, 2011$7.98M-3.3%
FY2010Dec 31, 2010$8.25M+41.4%
FY2009Dec 31, 2009$5.84M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$411.00K-70.4%
Q1 FY2026Mar 31, 2026$1.03M-2.9%
Q4 FY2025Dec 31, 2025$1.37M-3.2%
Q3 FY2025Sep 30, 2025$1.40M-4.1%
Q2 FY2025Jun 30, 2025$1.39M+8.7%
Q1 FY2025Mar 31, 2025$1.06M-36.9%
Q4 FY2024Dec 31, 2024$1.41M+100.9%
Q3 FY2024Sep 30, 2024$1.46M+2.4%
Q2 FY2024Jun 30, 2024$1.28M+75.0%
Q1 FY2024Mar 31, 2024$1.68M+153.3%
Q1 FY2019Mar 31, 2019$703.00K+50.5%
Q4 FY2018Dec 31, 2018$1.42M+46.7%
Q1 FY2018Mar 31, 2018$731.00K+23.7%
Q4 FY2017Dec 31, 2017$662.00K-54.8%
Q3 FY2017Sep 30, 2017$467.00K-36.1%
Q2 FY2017Jun 30, 2017$969.00K-13.9%
Q1 FY2017Mar 31, 2017$591.00K–
Q4 FY2016Dec 31, 2016$1.47M–
Q3 FY2016Sep 30, 2016$731.00K–
Q2 FY2016Jun 30, 2016$1.13M–

More Cerenome figures

See a number that looks wrong?